Tamoxifen has been the endocrine treatment of choice for patients with breast cancer. The development of selective aromatase inhibitors has offered an alternative management approach for patients in whom a hormonal approach is indicated.
Methods
The authors reviewed reports in which aromatase inhibitors were compared with tamoxifen for the treatment of metastatic disease, as well as information pertinent to their use as adjuvant therapy.
Results
Both nonsteroidal (anastrozole and letrozole) and steroidal (exemestane) aromatase inhibitors for metastatic disease appear to provide superior efficacy and a better toxicity profile in first- and second-line treatment of metastatic disease than tamoxifen. Early results from the ATAC trial suggest anastrozole is superior to tamoxifen for disease-free survival, particularly in receptor-positive patients, and in reducing the incidence of contralateral breast cancer.
Conclusions
Aromatase inhibitors have important roles in optimal management of postmenopausal patients with hormone-responsive metastases in both the adjuvant and advanced-disease settings.
References
1.
BeatsonG.T.. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.Lancet.1896; 2: 104–107.
2.
FisherB., CostantinoJ., WickerhamD.L.. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst.1998; 90: 1371–1388.
3.
LernerH.J., BandP.R., IsraelL., LeungB.S.. Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.Cancer Treat Rep.1976; 60: 1431–1435.
4.
WinerE.P., HudisC., BursteinH.J.. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.J Clin Oncol.2002; 20: 3317–3327.
5.
FisherB., CostantinoJ.P., WickerhamD.L.. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst.1998; 90: 1371–1388.
6.
BuzdarA., JonesS., VogelC.. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.Cancer.1997; 79: 730–739.
7.
LonningP.E., BajettaE., MurrayR.. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phawe II trial.J Clin Oncol.2000; 18: 2234–2344.
8.
BertelliG., GarroneO., MerlanoM.. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer.Proc Annu Meet Am Soc Clin Oncol.2002: 238. Abstract.
9.
BonneterreJ., ThurlimannB., RobertsonJ.F.. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.J Clin Oncol.2000; 18: 3748–3757.
10.
NabholtzJ.M., BuzdarA., PollakM.. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.J Clin Oncol.2000; 18: 3758–3767.
11.
Milla-SantosA., MillaL., RalloL.. Phase III trial of anastrozole (AN) vs tamoxifen (TAM) in postmenopausal (PM) patients (PTS) with hormone-dependent advanced breast cancer (ABC).Breast Cancer Res Treat.2000; 64: 54. Abstract 173.
12.
MouridsenH., SunY., GershanovichM.. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.J Clin Oncol.2001; 19: 2596–2606.
13.
ParidaensR., DirixL., BeexL.. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.Clin Breast Cancer.2000; 1(suppl 1): S19–S21.
14.
MouridsenH., SunY., GershanovichM.. Final survival analysis of the double-blind, randomized, multinational phase III trial of letrozole (Femara) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer.Breast Cancer Res Treat.2001; 69: 211.
15.
Tamoxifen for early breast cancer: an overview of the randomised trials.Early Breast Cancer Trialists’ Collaborative Group.Lancet.1998; 351: 1451–1467.
16.
FisherB., CostantinoJ., RedmondC.. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.N Engl J Med.1989; 320: 479–484.
17.
StewartH.J.. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer: Scottish Cancer Trials Breast Group.J Natl Cancer Inst Monogr.1992; 11: 117–120.
18.
FernoM., StalO., BaldetorpB.. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.Breast Cancer Res Treat.2000; 59: 69–76.
19.
FisherB., DignamJ., BryantJ.. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.J Natl Cancer Inst.2001; 93: 684–690.
20.
FisherB., DignamJ., BryantJ.. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.J Natl Cancer Inst.1996; 88: 1529–1542.
21.
JonesA.L., PowlesT.J., LawM.. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.J Clin Oncol.1992; 10: 1547–1552.
22.
BoccardoF., RubagottiA., AmorosoD.. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.J Clin Oncol.2001; 19: 4209–4215.
23.
GossP.. Anti-aromatase agents in the treatment and prevention of breast cancer.Cancer Control.2002; 9(2 suppl): 2–8.
24.
BaumM., on behalf of the ATAC Trialists’ Group. The ATAC (Arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal women.Breast Cancer Res Treat.2001; 69: 210.
25.
The ATAC Trialists’ Group.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomised trial.Lancet.2002; 359: 2131–2139.
26.
Phase III randomized study of adjuvant letrozole vs tamoxifen in postmenopausal women with operable, hormone receptor-positive breast cancer. Protocol IBCSG-1-98. Available at: http://Cancernet.nci.nih.gov. Accessed November 5, 2002.
27.
Phase III randomized study of letrozole versus placebo in women with primary breast cancer who have completed at least five years of adjuvant tamoxifen. Protocol NCCTG-CAN-MA17. Available at: http://cancer.gov/clinical_trials. Accessed November 5, 2002.
28.
Harper-WynneC., RossG., SacksN.. A pilot prevention study of the aromatase inhibitor letrozole; effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women.Breast Cancer Res Treat.2001; 69: 225. Abstract 136.
29.
DicklerM.N., RobsonM., HeerdtA.. Combined estrogen blockade of the breast with raloxifene and exemestane in postmenopausal women for breast cancer prevention.Breast Cancer Res Treat.2001; 69: 226. Abstract 138.
30.
BevilacquaG., SilingardiV., MarchettiP on behalf of ApreS Group, Italy. Exemestane for the prevention of breast cancer in postmenopausal unaffected carriers of BRACA1/2 mutations: Aromasin Prevention Study (ApreS).Breast Cancer Res Treat.2001; 69: 226. Abstract 139.
31.
ElledgeR.M., GreenS., CioccaD.. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.Clin Cancer Res.1998; 4: 7–12.
32.
BerryD.A., MussH.B., ThorA.D.. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.J Clin Oncol.2000; 18: 3471–3479.
33.
National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.J Natl Cancer Inst Monogr.2001; 30: 5–15.
34.
EllisM.J., CoopA., SinghB.. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for Erb-1 and/or Erb-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.J Clin Oncol.2001; 19: 3808–3816.
35.
LiptonA., MouridsenH., AliS.. Serum HER-2/neu and response to the aromatase inhibitor letrozole vs tamoxifen.Breast Cancer Res Treat.2001; 69: 210.
36.
ColomerR., LlombartA., RamosM.. Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study.Breast Cancer Res Treat.2001; 69: 242.
37.
LiptonA., AliS.M., LeitzelK.. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.J Clin Oncol.2002; 20: 1467–1472.
38.
RoseC., VtorayaO., PlyzanskaA.. Letrozole (Femara) vs anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer.Proc Annu Meet Am Soc Clin Oncol.2002: 131. Abstract.
